{"nctId":"NCT02680041","briefTitle":"18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment","startDateStruct":{"date":"2016-06-01","type":"ACTUAL"},"conditions":["Prostate Cancer"],"count":221,"armGroups":[{"label":"18F-fluciclovine PET CT","type":"EXPERIMENTAL","interventionNames":["Drug: 18F-fluciclovine PET CT"]}],"interventions":[{"name":"18F-fluciclovine PET CT","otherNames":["FACBC"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* History of histologically confirmed adenocarcinoma of the prostate post curative-intent local treatment (radical prostatectomy, local radiotherapy, brachytherapy).\n* Suspicion of recurrent prostate carcinoma after previous presumed definitive therapy for organ confined disease defined as :\n* Post prostatectomy: Detectable or rising PSA level that is \\>0.2 ng/mL with a second confirmatory level of \\>0.2 ng/mL\n* Post non-prostatectomy: PSA rise â‰¥ 2ng/mL over nadir\n* Negative or equivocal findings on standard-of-care imaging for restaging of disease in the previous 60 days consisting of: Whole-body 99mTc bone scintigraphy or NaF PET-CT; and either CT or MRI of the pelvis (or the abdomen and pelvis).\n* Being considered for salvage therapy\n* Any non-surgical local treatment such as previous cryotherapy, external beam radiation, or HiFU (Ultrasound) must have occurred at least 1 year in the past.\n* Previous brachytherapy treatment will have occurred at least 2 years in the past\n* Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Ongoing treatment with any systemic therapy intended for the treatment of prostate cancer (e.g., antiandrogen or LHRH agonist or antagonist)\n* Androgen deprivation therapy (ADT) in the past 3 months\n* History of bilateral orchidectomy\n* Inability to tolerate 18F-fluciclovine PET/CT","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Planned Treatment Through Detection of Disease.","description":"The change of management will be based on referring physician questionnaires completed pre- and post- 18F-fluciclovine PET/CT","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null}]},{"measurements":[{"groupId":"OG000","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null}]},{"measurements":[{"groupId":"OG000","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null}]},{"measurements":[{"groupId":"OG000","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Actual Treatment","description":"The change of management will be based on referring physician questionnaires completed pre- 18F-fluciclovine PET/CT and changes reported at 6 month follow-up.\n\nInvestigators were instructed to assess any clinically significant change from the revised management plan.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null}]},{"measurements":[{"groupId":"OG000","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null}]},{"measurements":[{"groupId":"OG000","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null}]},{"measurements":[{"groupId":"OG000","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"The Rate of Detection of Any Disease Site by 18F-fluciclovine PET/CT in the Study Population","description":"The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"122","spread":null}]}]}]},{"type":"SECONDARY","title":"The Rate of Detection of Disease in 1) Prostate and Prostate Bed and 2) Extra-prostatic Regions With 18F-fluciclovine PET/CT in the Study Population","description":"The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT 1) in the pelvis and 2) distally","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null}]}]}]},{"type":"SECONDARY","title":"The Positive Predictive Value (PPV) of 18F-fluciclovine PET/CT for Regional Disease Compared to Biopsy in Those Patients Who Undergo Biopsy or in Case of Bony Disease a Correlation With MRI or Biopsy","description":"Based on the ratio of positive findings in the pelvis on 18F-fluciclovine PET/CT which are confirmed by histological examination of tissue or MRI","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"The PPV of 18F-fluciclovine PET/CT for Distant Disease Compared to Biopsy in Those Patients Who Undergo a Biopsy or in Case of Bony Disease a Correlation With MRI or Biopsy","description":"Based on the ratio of positive findings outside the pelvis on 18F-fluciclovine PET/CT which are confirmed by histological examination of tissue or MRI","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":213},"commonTop":["Diarrhoea","Headache","Constipation","Haematuria","Nocturia"]}}}